Veracyte is a molecular diagnostics company that develops and commercializes genomic tests for cancer risk stratification and treatment guidance across multiple cancer types including breast, prostate, thyroid, and bladder cancers, as well as emerging liquid biopsy solutions for treatment monitoring. The company generates revenue by performing laboratory-developed tests in its CLIA-certified laboratories and by distributing in vitro diagnostic kits to clinical laboratories and healthcare providers globally, with revenue recognized when test results are delivered to ordering physicians and based on expected reimbursement from payers such as Medicare, Medicaid, and commercial insurers. Veracyte serves physicians, clinical laboratories, hospital networks, and international distributors, while also partnering with pharmaceutical companies on companion diagnostic collaborations, though its business faces inherent complexity from variable payer reimbursement rates, regulatory compliance requirements across jurisdictions, reliance on contract manufacturers and sole-source suppliers, and competitive pressures from larger established diagnostics companies.